GSK Boosts Its Infectious Disease Portfolio With Brexafemme License

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

The pharma licensed global rights to Scynexis’s Brexafemme, a first-in-class triterpenoid antifungal approved for treat and prevent recurrence of vaginal yeast infections, for $90m up front.

GSK HQ
GSK adds a novel antifungal to its infectious disease portfolio • Source: Shutterstock

Licensing global development and commercial rights for antifungal Brexafemme (ibrexafungerp) strengthens GSK plc’s portfolio in infectious diseases while improving the financial health of Scynexis, Inc., which said the deal would put the first-in-class triterpenoid agent in the best hands to realize its market potential in the treatment and prevention of recurrent vaginal yeast infections.

New Jersey-based Scynexis said 30 March that GSK would pay $90m up front for global rights to Brexafemme, an oral...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.